Life sciences glossary C–D
Life sciences glossary C–D

The following Life Sciences practice note provides comprehensive and up to date legal information covering:

  • Life sciences glossary C–D
  • CE marking
  • Centralised procedure
  • Clinical data
  • Clinical evaluation
  • Clinical investigation
  • Clinical investigation plan
  • Clinical study
  • Clinical trial
  • Clinical Commissioning Groups (CCGs)
  • More...

Life sciences glossary C–D

IP COMPLETION DAY: 11pm (GMT) on 31 December 2020 marks the end of the Brexit transition/implementation period entered into following the UK’s withdrawal from the EU. At this point in time (referred to in UK law as ‘IP completion day’), key transitional arrangements come to an end and significant changes begin to take effect across the UK’s legal regime. This document contains guidance on subjects impacted by these changes. Before continuing your research, see Practice Note: What does IP completion day mean for Life Sciences?

A–B | E–H | I–N | O–P | Q–U.

CE marking

The CE (Conformité Européene—meaning European Conformity) mark is a mandatory conformity marking for certain products sold within the EEA, including medical devices. It:

  1. shows that the manufacturer has checked that these products meet EU safety, health or environmental requirements

  2. is an indicator of a product’s compliance with EU legislation

  3. allows the free movement of products within the European market

See Practice Note: An introduction to the regulation of medical devices.

Centralised procedure

One of the procedures available for the authorisation of medicinal products in the EU. It is the mandatory procedure for the following types of medicinal products: products derived from biotechnology, for orphan medicinal products and for medicinal products for human use which contain an active substance authorised in the Community after 20 May 2004 (date of entry into force of Regulation (EC)

Related documents:

Popular documents